Amy Sherman, Jessica Tuan, Valeria D Cantos, Oladunni Adeyiga, Scott Mahoney, Ana M Ortega-Villa, Amy Tillman, Jennifer Whitaker, Amanda S Woodward Davis, Brett Leav, Ian Hirsch, Jerald Sadoff, Lisa M Dunkle, Peter B Gilbert, Holly E Janes, James G Kublin, Paul A Goepfert, Karen Kotloff, Nadine Rouphael, Ann R Falsey, Hana M El Sahly, Magdalena E Sobieszczyk, Yunda Huang, Kathleen M Neuzil, Lawrence Corey, Beatriz Grinsztejn, Glenda Gray, Martha Nason, Lindsey R Baden, Cynthia L Gay
BACKGROUND: Although the SARS-CoV-2 vaccines are highly efficacious at preventing severe disease in the general population, current data are lacking regarding vaccine efficacy (VE) for individuals with mild immunocompromising conditions. METHODS: A post-hoc, cross-protocol analysis of participant-level data from the blinded phase of four randomized, placebo-controlled, COVID-19 vaccine phase 3 trials (Moderna, AstraZeneca, Janssen, and Novavax) was performed. We defined a "tempered immune system" (TIS) variable via a consensus panel based on medical history and medications to determine VE against symptomatic and severe COVID-19 cases in TIS participants versus non-TIS (NTIS) individuals starting at 14 days after completion of the primary series through the blinded phase for each of the four trials...
April 10, 2024: Clinical Infectious Diseases